Figure 5From: Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyTime to first COPD exacerbation. COPD, chronic obstructive pulmonary disease; UMEC, umeclidinium; VI, vilanterol.Back to article page